Media headlines about Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Novelion Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.8434794304083 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Several brokerages recently commented on NVLN. ValuEngine cut shares of Novelion Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 12th. Royal Bank Of Canada set a $9.00 price objective on shares of Novelion Therapeutics and gave the company a “hold” rating in a research note on Tuesday, August 8th. Zacks Investment Research upgraded shares of Novelion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, Bloom Burton reiterated an “accumulate” rating on shares of Novelion Therapeutics in a research report on Monday, June 19th.
Novelion Therapeutics (NVLN) traded up 0.15% during midday trading on Wednesday, reaching $6.90. 8,026 shares of the company were exchanged. The firm’s market capitalization is $128.67 million. The company has a 50-day moving average of $7.53 and a 200 day moving average of $9.25. Novelion Therapeutics has a 52 week low of $6.62 and a 52 week high of $13.80.
Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.04). The business had revenue of $40.90 million during the quarter, compared to the consensus estimate of $36.86 million. Equities analysts predict that Novelion Therapeutics will post ($1.66) earnings per share for the current year.
WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Novelion Therapeutics (NVLN) Stock Price” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/09/20/novelion-therapeutics-nvln-given-daily-media-sentiment-rating-of-0-13.html.
Novelion Therapeutics Company Profile
Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.
Receive News & Ratings for Novelion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.